Literature DB >> 10452789

Bronchoconstrictor additives in bronchodilator solutions.

M J Asmus1, J Sherman, L Hendeles.   

Abstract

Nebulized bronchodilator solutions are available in the United States as both nonsterile and sterile-filled products. Sulfites, benzalkonium chloride (BAC), or chlorobutanol are added to nonsterile products to prevent bacterial growth, but there have been reports of contaminated solutions containing preservatives. Ethylenediamine tetraacetic acid (EDTA) is added to some products to prevent discoloration of the solution. With the exception of chlorobutanol, all of these additives are capable of inducing bronchospasm in a concentration-dependent manner. However, it is rarely apparent to the patient or health care provider that the additive diminishes the bronchodilator effects. Older products (eg, isoproterenol and isoetharine) contain enough sulfites to produce bronchospasm in most patients with asthma, even in those without a prior history of sulfite sensitivity. Bronchoconstriction from inhaled BAC is cumulative, prolonged, and correlates directly with basal airway responsiveness. The multidose dropper bottle of albuterol contains 50 microg BAC/dose, which is below the threshold for bronchoconstriction whereas the screwcap unit-dose vial contains 300 microg/dose, which is above the threshold for many patients. If the screwcap product is used in the emergency department, a patient could receive as much as 1800 microg of BAC in the first hour. Three sterile-filled unit dose albuterol products contain no additives, whereas a fourth, (manufactured by Dey Laboratories) contains 300 microg of EDTA, which is also below the threshold dose for bronchoconstriction. Only additive-free sterile solutions should be used for hourly or continuous nebulization of albuterol. The multidose dropper bottle or the Dey product can be used when the interval between doses is longer, whereas the screwcap product should not be used for acute therapy. Ipratropium is available only as a sterile, additive-free unit-dose vial, as is levalbuterol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452789     DOI: 10.1016/s0091-6749(99)70274-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Paradoxical bronchospasm from benzalkonium chloride (BAC) preservative in albuterol nebulizer solution in a patient with acute severe asthma. A case report and literature review of airway effects of BAC.

Authors:  Mathew George; Saumya Vinod Joshi; Emily Concepcion; Haesoon Lee
Journal:  Respir Med Case Rep       Date:  2017-03-06

2.  Evaluation of pulmonary toxicity of benzalkonium chloride and triethylene glycol mixtures using in vitro and in vivo systems.

Authors:  Doyoung Kwon; Yeon-Mi Lim; Jung-Taek Kwon; Ilseob Shim; Eunji Kim; Doo-Hee Lee; Byung-Il Yoon; Pilje Kim; Hyun-Mi Kim
Journal:  Environ Toxicol       Date:  2019-02-20       Impact factor: 4.119

Review 3.  Hypersensitivity Reactions to Food Additives-Preservatives, Antioxidants, Flavor Enhancers.

Authors:  Mateusz Witkowski; Halina Grajeta; Krzysztof Gomułka
Journal:  Int J Environ Res Public Health       Date:  2022-09-13       Impact factor: 4.614

4.  Benzalkonium chloride induced bronchoconstriction in patients with stable bronchial asthma.

Authors:  Byoung Hoon Lee; Sang-Hoon Kim
Journal:  Korean J Intern Med       Date:  2007-12       Impact factor: 3.165

Review 5.  Adverse reactions to the sulphite additives.

Authors:  Hassan Vally; Neil LA Misso
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2012

6.  Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.

Authors:  Daniel P Cashman
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

Review 7.  Asthma-inducing potential of 28 substances in spray cleaning products-Assessed by quantitative structure activity relationship (QSAR) testing and literature review.

Authors:  Niels Hadrup; Marie Frederiksen; Eva B Wedebye; Nikolai G Nikolov; Tanja K Carøe; Jorid B Sørli; Karen B Frydendall; Biase Liguori; Camilla S Sejbaek; Peder Wolkoff; Esben M Flachs; Vivi Schlünssen; Harald W Meyer; Per A Clausen; Karin S Hougaard
Journal:  J Appl Toxicol       Date:  2021-07-11       Impact factor: 3.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.